Compare BioNTech SE - ADR (BNTX) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Trip.com Group Ltd — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Trip.com Group Ltd trades at $42.65 (market cap $26.95B). The key difference: Trip.com Group Ltd is the larger of the two by market cap, and Trip.com Group Ltd pays a 0.42% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | TCOM | |
|---|---|---|
Market Cap | $22.86B | $26.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $78.96 |
52-Week Low | $83.89 | $39.84 |
Enterprise Value | $6.53B | $19.65B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
TCOM trades at $42.36, down 1.03% on the day, with a bearish technical signal and recent earnings misses. The stock shows strong fundamentals with a P/E of 6.36, net income margin of 48.65%, and robust cash flow from operations of $19.63 billion in 2024. However, Q1 2026 earnings missed estimates, and Q2 revenue guidance of 3%-8% growth disappointed investors, contributing to recent price weakness.
The outlook is mixed; strong profitability and low valuation offer upside toward the $56.72 consensus price target, but near-term headwinds include regulatory scrutiny and muted guidance. Risks involve antitrust investigations and domestic travel dependency, yet institutional sentiment remains positive with 67% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
